Meridian Bioscience (VIVO) Tops Q1 EPS by 4c, Reaffirms Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. RELIANCE:I
2. LYB
3. BP
4. REGN
5. LITE
6. CL
7. OKTA
8. NWG
9. NWG:LN
10. PERI

Go back to Meridian Bioscience (VIVO) Tops Q1 EPS by 4c, Reaffirms Guidance

Meridian Bioscience Reports First Quarter Fiscal 2020 Operating Results and Reaffirms 2020 Guidance

February 7, 2020 7:30 AM EST

CINCINNATI, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2019.

First Quarter Fiscal 2020 Highlights:

Diagnostics segment delivered nearly $35 million in revenues; fourth consecutive quarter above $33 million, signaling continued stabilization of this business;Positive customer feedback for our revogene molecular diagnostics system continues to build;Diagnostics segment new product development spending increased $1 million, as positive progress continues on key new instrument platforms;Lower ordering patterns of top IVD manufacturing... More